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Background: The phosphodiesterase (PDE3A) 3A protein gene product regulates contractile function, via its co-localization in the cardiac myocyte 
phospholamban-Serca2a microdomain. Drugs that inhibit PDE3A (PDEIs) are positive inotropic and lusitropic agents, but exhibit therapeutic 
response heterogeneity that may be explained by varying degrees of PDEI tolerance. This led us to search for functionally important genetic variation 
in the PDE3A gene.
Methods and Results: We identified a 29 nt insertion/deletion (Ins/Del, allele frequencies 0.41/0.59) polymorphism in the PDE3A promoter 
region, at -1120 from one of the start sites. The Ins contains a binding site for ectotropic viral integration site-1 (Evi-1), a transcription factor that is 
markedly (by 16 fold) induced by cAMP. Evi-1 typically functions as a strong transcriptional repressor. In LVs explanted from end-stage HF patients 
undergoing transplantation, patients treated with enoximone who were either homozygous or heterozygous for PDE3A Del (Del carriers, n= 9) PDE3A 
mRNA abundance was increased 2.1 ± 0.3 fold compared to Del patients not receiving enoximone (n = 19, p <0.001). In contrast, LV samples from 
patients treated with enoximone who were homozygous for the Ins (Ins/Ins) did not exhibit an increase in PDE3A gene expression (1.1 ± 0.3 fold, 
p = 0.7). In neonatal rat cardiac myocytes transfected with either Ins or Del PDE3A promoter-luciferase constructs, agents that increased cAMP 
markedly increased transcriptional activity in Del but not Ins.
Conclusions: A 29 nt Ins/Del polymorphism in the PDE3A promoter regulates PDE3A gene expression, whereby the major allele, Del variant 
exhibits increased PDE3A expression in response to agents that increase cAMP. This provides a molecular explanation of tolerance to PDE3 inhibitors. 
In contrast, patients who are Ins/Ins exhibit no such up-regulation of PDE3A gene expression in response to cAMP augmenting agents, and as a 
result may not be predisposed to drug tolerance. This pharmacogenetic hypothesis should be tested further, in chronic HF patients treated with PDE3 
inhibitors.
